Below is a compilation of important resources regarding issues related to COVID-19.
1. Understanding Vaccine Landscape
- Draft landscape and tracker of COVID-19 candidate vaccines, WHO
- Coronavirus Vaccine Tracker, New York Times
- COVID-19 Vaccine Tracker, India
- COVID-19 Vaccine Trials & testing
- COVID-19 Vaccine Tracker, Parliamentary Constituency wise in India, Geographic insights, Harvard Centre for Population & Development Studies
- COVID-19 Vaccine Tracker, Jeff Craven, Regulatory Affairs Professionals Society
- Update on COVID-19 Vaccine Development, WHO
2. Clinical Registry Trials & Ingredients
- Covishield: Clinical Registry Details and List of Ingredients
- Covaxin: Clinical Registry Details and List of Ingredients
- Sputnik: Clinical Registry Details | About Sputnik
- Pfizer: FDA Briefing document
- Moderna: FDA Briefing document
- Johnson & Johnson: FDA Briefing document
- Clinical Registry Details of Other vaccines
3. Vaccine Frequently Asked Questions (FAQs)
- India FAQs, Ministry of Health & Family Welfare
- Centers for Disease Control and Prevention (CDC), FAQs
- ICMR FAQs in vernacular languages
- Sputnik FAQs, Apollo Hospitals
- WHO FAQs, COVID-19 vaccines.
- Delta and Delta Plus Variants FAQs - Government of India
- Guide to Parents: Kids and Delta variant, New York Times
4. Vaccine Procurement Data of Countries
- Vaccine Procurement tracker, Duke University
- Details of successive orders placed by the Government of India (GoI) for COVID-19 vaccines - Affidavit of GoI in the Supreme Court on 26 June 2021.
5. Studies on Vaccine efficacy
- Covaxin efficacy results, Bharat Biotech
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, The New England Journal of Medicine
- Covishield efficacy study and study, The Lancet
- Further evidence on vaccine studies: Safety and efficacy of Pfizer & AstraZeneca vaccines
- Protective effect of COVID-19 vaccine among health care workers during the second wave of the pandemic in India
- Efficacy of NVX-CoV2373 (Novavax) COVID-19 Vaccine against the B.1.351 Variant
- Interim results of Phase 1–2a Trial of Ad26.COV2.S (Johnson & Johnson) COVID-19
Vaccine
6. Studies on Breakthrough cases
- COVID-19 vaccine breakthrough case investigation and reporting, CDC
- Breakthrough SARS-CoV-2 infections in an eastern state of India: A preliminary report
- Tolerability and Immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 (AZD1222) - Lancet
7. Virus Variants Tracking
- Tracking SARS-COV-2 variants, WHO
- Coronavirus Variants and Mutations, The New York Times
- Surveillance for SARS-CoV-2 Variants, CDC
- SARS-CoV-2 Variant Classifications and Definitions, CDC
- COVID-19 Variant Tracker, Axios Visuals
- COVID-19 Variant Lineage, PANGO lineages
- Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India
- Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
- The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies.
8. Studies on Virus Variants
- Vaccines highly effective against hospitalization from Delta variant, Public Health England
- Pfizer vaccines neutralize Delta and other COVID-19 variants, Nature study
- Immunogenicity of Johnson & Johnson vaccine against SARS-CoV-2 variants in humans, Nature study
- Pfizer, AstraZeneca vaccines protect against Delta variant: Lancet study & Public Health England
- Covaxin effectively neutralises Delta and Alpha variants of COVID-19: National Institutes of Health and Lancet Study
- Efficacy of the ChAdOx1 nCoV-19 Covishield COVID-19 Vaccine against the B.1.351 Variant
9. Common Misinformation & Facts
- WHO Mythbusters
- Factly- English Fact Checks
- Health microsite, Factly
- Harvard T.H. Chan School of Public Health-India Research Centre (IRC), Mythbusters, COVID-19 resources and IRC toolkit
Last updated on 3 July 2021
